More Industry News & Trends

More News

Bioventus and UnitedHealthcare Sign Contract for HA-Based Knee Injections

Bioventus reported Sept. 9 that it has signed an agreement with UnitedHealthcare employer and individual commercial plans to cover Durolane and Gelsyn-3 injections. Durolane is a single injection o...

Fundus Imaging Systems with Advanced Features Will Drive Growth as Chronic Disease Booms, Need for Routine Screening Increases

The market will generate $733 million in 2019 and is expected to grow 4.3 percent a year over the next five years. Fundus images are used to monitor patients with chronic conditions, such as diabet...

Bausch + Lomb Licenses Tatvum’s IOL Designs for Correcting Astigmatism, Presbyopia

Bausch + Lomb, a division of Bausch Health, announced Oct. 1 that it obtained worldwide rights to new intraocular lens (IOL) designs from Tatvum Research, of Aliso Viejo, California. The two compan...

Female Ophthalmology Residents Perform Fewer Procedures than Male Peers, Study Says

Female ophthalmology residents in the US perform fewer procedures than male counterparts, according to a study published in July 2019 by JAMA Ophthalmology. Lead author Dan Gong, MD, of Columbia Un...

Genentech, Roche Scientists Publish Results of Algorithm Designed to Predict DR Progression

Researchers from Genentech and Swiss parent company Roche have developed an algorithm designed to predict the progression of diabetic retinopathy (DR) in patients. Positive study results were publi...

LumiThera Begins Enrollment in Phase III Study of Photobiomodulation in Dry AMD

LumiThera, of Poulsbo, Washington, has enrolled the first patient in a Phase III study of its photobiomodulation system as a treatment for dry age-related macular degeneration (dry AMD). The random...

Nicox Candidate NCX 470 Meets Endpoints in Phase II Trial in Glaucoma or OHT

France-based Nicox announced Oct. 2 that NCX 470 met primary and secondary endpoints in a Phase II trial in open-angle glaucoma and ocular hypertension. NCX 470 is a second-generation nitric oxide ...

Novartis, Microsoft Partner on AI Lab; Macular Degeneration is Early Target

Novartis has created an artificial intelligence (AI) innovation lab and selected Microsoft as its AI and data-science partner for this multiyear effort, the companies announced Oct. 1. The lab is i...

Noveome Initiates Phase I Trial Evaluating Intranasal Delivery of ST266 in Patients with Ocular Hypertension

Noveome Biotherapeutics, of Pittsburgh, announced Sept. 26 that it had initiated a Phase I trial of ST266, delivered intranasally in patients diagnosed with ocular hypertension who have not yet dev...

Ocugen and CanSinoBIO Enter Partnership to Develop Gene Therapy for Inherited Retinal Diseases

Ocugen announced Sept. 30 that it had entered into a strategic partnership with CanSino Biologics to develop Ocugen’s gene therapy product candidates for inherited retinal diseases. Under the agree...

Santen Gains Approval in Japan for Alesion LX to Treat Allergic Conjunctivitis

Santen Pharmaceutical announced Sept. 20 that it gained marketing approval in Japan of Alesion LX Ophthalmic Solution 0.1% for allergic conjunctivitis. Santen, based in Japan, also announced a join...

Second Sight Announces $2.4 Million NIH Grant to Develop Spatial Localization Technology for Orion Implant

Second Sight announced Oct. 1 that it had received a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology. The company, ...

VirtaMed Collaborates With Smith & Nephew for Surgeon Training Simulator

VirtaMed announced Sept. 9 that it is combining its simulation technology with Smith & Nephew’s surgical instruments to create surgeon training modules for knee, shoulder, and hip arthroscopy. All ...

NeuroStructures to Offer Pinnacle Spine’s Lateral Spine Surgery Solutions

Announced Sept. 3, NeuroStructures and Pinnacle Spine entered into a manufacturing and distribution agreement. NeuroStructures now has access to Pinnacle’s lateral-access retractors, interbody impl...

Bone Solutions Signs Private-Label Licensing Agreement With Onkos Surgical

Bone Solutions announced Aug. 28 that it signed a private-label licensing agreement with Onkos Surgical for OsteoCrete bone filler technology. Bone Solutions’ OsteoCrete was the first magnesium-bas...

Surgical Robot Market Growing at a Compound Rate of 31 Percent Through 2024

Orthopedic robots offer an unprecedented opportunity to reduce surgical complications and operating time, improve results, and extend the life of implants. These benefits stem from increased precis...

SI-BONE’s iFuse Receives Coverage

SI-BONE announced Sept. 3 that its minimally invasive sacroiliac joint fusion device, iFuse, received coverage from Wellmark Blue Cross Blue Shield. This system covers over 1.5 million members acro...

JAAOS Article Reports Laser Spine Surgery Poses More Risks Than Benefits

Laser spine surgery has become popular among patients due to persuasive press coverage. However, the Journal of the American Academy of Orthopaedic Surgeons published an article Sept. 1 by Kris Rad...

WishBone Signs Agreement to Distribute OsteoCrete

WishBone Medical signed a private-label distribution agreement with Bone Solutions for OsteoCrete, a resorbable, magnesium-based bone void filler, the company announced Aug. 15. This agreement give...

Aerie Pharmaceuticals Receives CHMP Nod for Rhokiinsa (Rhopressa) in the EU

Aerie Pharmaceuticals said Sept. 20 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval of the marketing authorization application (M...

Aerie Pharmaceuticals Applies for US FDA Approval to Produce Rocklatan at Facility in Ireland

Aerie Pharmaceuticals has submitted a prior approval supplement (PAS) to the US FDA to permit production of its glaucoma drug Rocklatan for sale in the United States in Aerie’s new manufacturing pl...

Aldeyra Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

Aldeyra Therapeutics announced Sept. 24 that the US FDA had granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR)—a fibroproliferative disorder that...

Amydis Awarded $1.5 Million NIH Grant for Ophthalmic Diagnostic Compound to Detect Brain Disease

Amydis, a company developing drugs to detect amyloid-related diseases, has received $1.5 million from the National Institute on Aging of the National Institutes of Health (NIH), the San Diego compa...

Boehringer Ingelheim Partners with Inflammasome to Develop Retinal Therapies

German company Boehringer Ingelheim and Inflammasome Therapeutics, of Newton, Massachusetts, announced Sept. 20 that they had entered into a co-development and license agreement to develop up to th...

First Patient Dosed in Phase III Clinical Trial of Dextenza for Allergic Conjunctivitis

Ocular Therapeutix, of Bedford, Massachusetts, announced Sept. 24 that it had dosed the first patients in its Phase III clinical trial of Dextenza for the treatment of symptoms of allergic conjunct...

FDA’s Collaboration with Canada, Australia on Cancer Drugs Bears First Fruit

The US FDA announced Sept. 17 that it had entered into a collaboration with Australia and Canada to provide for cooperative review of applications for cancer drugs, allowing for simultaneous decisi...

Graybug Vision Initiates Phase IIa Trial in Macular Edema Secondary to DME or RVO

Graybug Vision, of Redwood City, California, announced Sept. 18 that it has begun a Phase IIa study of GB-102 in patients with macular edema (ME) secondary to diabetic macular edema (DME), retinal ...

Konan Medical’s EyeKinetix Pupillograph Now Available in the US

Konan Medical has announced that its EyeKinetix pupillograph is FDA listed and now available for sale in the US. EyeKinetix is Konan’s second-generation pupillograph, which the company says is smal...

Nicox Reports Net Revenue of €5.6 Million in First Half of 2019, a Big Jump Year over Year

The French company Nicox reported on Sept. 17 that the company and its subsidiaries had taken in €5.6 million ($6.1 million US) for the six months ending June 30, compared with €300 thousand ($330 ...

18-Month Results from First OMNI Cases in Europe Suggest Long-Term IOP and Medication Reduction

Sight Sciences announced Sept. 18 that findings from a pilot study of the company’s OMNI Surgical System suggest that the system may provide significant long-term reductions in intraocular pressure...

New Schwind ATOS Femtosecond Laser Offers Minimally Invasive Lenticule Extraction

German laser company Schwind, at the recent ESCRS congress in Paris, introduced a new femtosecond laser, Schwind ATOS, which features an advanced, minimally invasive lenticule extraction called the...

Tarsius Pharma Announces FDA Acceptance of IND Application for TRS01

Israeli company Tarsius Pharma announced Sept. 24 the acceptance of its investigational new drug (IND) application for its TRS01, a novel drug to treat blinding ocular diseases, by the US FDA. The ...

Ophthalmic Company Revenue Increases 7.3 Percent in Q2-2019

Public company reports are in for Q2-2019, and overall ophthalmic revenue totaled $9.5 billion, an increase of 7.3 percent over the same quarter last year. The total includes Market Scope estimates...

Surgeons Report 6.5 Percent Growth in Q2-2019 US Ophthalmic Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 6.5 percent in Q2-2019 compared with the same quarter last year, according to Market Scope’s latest surveys. Growth was sporadicall...

Alcon PanOptix Gains US Approval, Is Expected to Expand PC-IOLs’ Share of Market

Alcon’s PanOptix trifocal IOL gained US FDA approval on Aug. 27, becoming the first trifocal approved in the country and broadening the options available to patients seeking spectacle independence....

RxSight Begins Initial Commercialization of Light Adjustable Lens in the US

RxSight has launched its Light Adjustable Lens (LAL) at 10 vision centers to date in the US. These practices are among the most well-known and respected centers in the country. The initial five sit...

J&J Vision Launches TECNIS Synergy IOL

Johnson & Johnson Vision launched its TECNIS Synergy intraocular lens on Sept. 16 in Paris. The IOL is available in Europe, Australia, and New Zealand. The company describes the Synergy as a presby...

BVI’s PhysIOL Introduces FineVision Triumf IOL

Beaver-Visitec International announced Sept. 12 that its PhysIOL subsidiary launched the FineVision Triumf trifocal extended depth of focus (EDOF) IOL in Europe in conjunction with the 2019 Congres...

New World Medical Launches Ahmed ClearPath Glaucoma Drainage Device

New World Medical announced Aug. 22 the launch of the Ahmed ClearPath glaucoma drainage device. Developed in partnership with glaucoma surgeons, the Ahmed ClearPath is available in two sizes, 350 m...

STAAR to Begin US Clinical Trial of EVO and EVO+ Visian ICLs

STAAR Surgical announced Aug. 27 that it received a green light from the US FDA to begin a human clinical study of its phakic EVO and EVO+ Visian Implantable Collamer Lenses (ICLs) for myopia. The ...

CMS Plans 15 Percent Cut in Cataract Surgery Reimbursement for 2020

Ophthalmologists will see a 15 percent reduction in cataract surgery reimbursement in 2020 under proposed changes released in July by the Centers for Medicare and Medicaid Services. The American Ac...

Scientists Test Implant to Stimulate Optic Nerve in Blind Patients

Scientists at universities in Switzerland and Italy are developing an intraneural electrode designed to stimulate the optic nerve to provide visual signals to the blind. They published results of s...

Novartis Leads the Race to Launch a New Anti-VEGF for Wet AMD

Novartis expects to learn in October if it has obtained US FDA approval of a biologics license to market brolucizumab for the treatment of neovascular age-related macular degeneration. Approval cou...

US, EU Accept Marketing Application for Abicipar Pegol in Patients with Wet AMD

Allergan and Molecular Partners announced Sept. 9 that the US FDA accepted a biologics license application and the EMA validated a marketing authorization application for abicipar pegol in patients...

Cataract Surgery Continues to Drive Sales of Single-Use Surgical Products

Factors that will drive healthy growth in the single-use ophthalmic surgical product market during the next five years include an aging world population—leading to steady growth in cataract surgeri...

Advanced Fundus Imaging Features Will Drive Growth as Chronic Disease Booms, Routine Screening Rises

Fundus images are used to monitor patients with chronic conditions, such as diabetes, in an effort to catch pathology as early as possible and preserve vision. In developing countries, as rates of ...

Aerie Pharmaceuticals Leads Latest Fundraising Efforts with $316 Million in Financing

Aerie Pharmaceuticals led recent fundraising efforts by ophthalmic companies, raising $275 million in convertible senior notes, plus $41.25 million in options, for $316 million in total. Market Sco...

2019 AAO Meeting Expected to Draw 24 Thousand to San Francisco

The annual meeting of the American Academy of Ophthalmology gets underway on Oct. 11 with retina and refractive subspecialty days. Additional subspecialty days for cornea, glaucoma, neuro-ophthalmo...

September 2019 Ophthalmic News Briefs

Novartis to Evaluate Iconic’s Ophthalmology Program Novartis will evaluate Iconic Therapeutics’ ophthalmology program under a new option agreement, Iconic announced Aug. 22. The South San Francisco...

Market Scope Weekly Ophthalmic Surgeon and Industry Polls for September 2019

Market Scope Weekly Surgeon Poll for July 22-28, 2019

J&J Vision Launches TECNIS Synergy IOL in Europe, Australia, and New Zealand

BVI’s PhysIOL Launches FineVision Triumf EDOF Trifocal IOL

Alcon Launches Two Enhancements to WaveLight Refractive Suite

Alcon announced Sept. 9 that it has launched two additions to its WaveLight Refractive Suite for LASIK surgery: complementary diagnostic software intended to provide the most enhanced corneal profi...

Adverum Reports Positive Results from First Cohort in Phase I Trial of Gene Therapy to Treat Wet AMD

Adverum Biotechnologies announced on Sept. 11 positive 24-week clinical data from the first cohort of six patients treated with a one-time intravitreal (IVT) dose of ADVM-022 in the company’s Phase...

Aurinia Looks to Raise $40 Million with ‘At the Market’ Offerings

Aurinia Pharmaceuticals announced Sept. 13 that it would sell, through periodic “at the market” (ATM) offerings, common shares with an aggregate offer price of up to $40 million. Aurinia said it in...

CorNeat Vision Completes Preclinical Phase for Synthetic Cornea and Scleral Patch

CorNeat Vision, of Israel, announced Sept. 9 that it had completed the preclinical stage for its investigational corneal implant and synthetic, nondegradable scleral patch. The company’s product ca...

Lineage Cell Therapeutics Sells OnoCyte Shares, Raises $6.6 Million

Lineage Cell Therapeutics announced Sept. 11 that it had sold 4 million shares of common stock of OncoCyte at $1.66 per share. Gross proceeds from the sale were $6.6 million. The Carlsbad, Californ...

MST Innovations Introduces the Scleral IOL Fixation Solutions Pack

MicroSurgical Technology has introduced its Scleral IOL Fixation Solutions Pack, designed to streamline the double-needle scleral IOL fixation technique with new instruments packaged together to su...

Nevakar Completes Enrollment in Phase III Study of Drug Candidate to Slow Myopia in Children

Nevakar announced Sept. 11 that it had completed enrollment in a Phase III study evaluating the ability of its candidate NVK-002 to slow the progression of myopia in children. NVK-002 is a preserva...

Canon Xephilio Optical Coherence Tomography Device Gets FDA 510(k) Clearance

Canon’s Xephilio OCT-A1 Optical Coherence Tomography device has been cleared for sale in the US, the company announced Sept. 17. The Xephilio OCT-A1 has a scanning speed of 70 thousand A-scans per ...

Vertical Pharmaceuticals Files NDA for Candidate for Droopy Eyelid

Vertical Pharmaceuticals announced Sept. 18 that it has submitted a new drug application to the US FDA for RVL-1201, its oxymetazoline hydrochloride ophthalmic solution for acquired blepharoptosis,...

Wize Pharma Reaches Licensing Deal for Ophthalmic Nonviral Gene Therapy Technology

Wize Pharma, of Israel, has entered into an exclusive license agreement with US-based Copernicus Therapeutics for rights to develop and commercialize products based on Copernicus’ nonviral gene the...

CARLSMED Merges With Precisive Surgical

Medical technology company CARLSMED announced July 17 that it completed a merger with Precisive Surgical, a spine imaging company. The end goal of this deal is to create a complete, personalized su...

Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driver

The world’s aging population--leading to steady growth in cataract surgeries--and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmi...

Cigna to Cover Full Price of Luxturna, Zolgensma Gene Therapies in the US

Cigna Health will cover the price of gene therapies Luxturna and Zolgensma in the US, ensuring patients have no out-of-pocket costs, the health service company announced Sept. 5. To do so, Cigna ha...

Keranova Raises $26.5 Million in Second Round for Cataract Surgery Technology

France-based Keranova announced Sept. 10 that it raised $26.5 million (€24 million) in a second round of financing. The company is developing a system designed to combine several steps of cataract ...

Biotissue Expands Sales Force Following $82.25M Financing by Parent TissueTech

Biotissue announced Sept. 11 that it is expanding its sales force for its cryopreserved amniotic membrane products for ophthalmic use through funding raised by parent TissueTech. TissueTech reporte...

Novartis Announces EU Approval of Lucentis for Preterm Infants with Retinopathy of Prematurity

The Swiss company Novartis announced Sept. 6 the European approval of Lucentis (ranibizumab) for preterm infants with retinopathy of prematurity (ROP), making it the first and only licensed drug tr...

Kowa Submits IND to US FDA to Study its Glanatec Rho Kinase Inhibitor for Corneal Endothelial Diseases

The Japanese company Kowa announced Sept. 3 that it had submitted an investigational new drug (IND) application to the US FDA to begin a Phase II study for its ripasudil hydrochloride hydrate Rho k...

Allergan and Molecular Partners Announce Acceptance of Applications in US, EU for Abicipar Pegol in Patients with Wet AMD

Allergan and Molecular Partners announced Sept. 9 that the US FDA had accepted a biologics license application and the European Medicines Agency (EMA) had validated a marketing authorization applic...

Ocuphire Completes Enrollment in Phase II Trials of Nyxol Drops for Glaucoma

Ocuphire Pharma, of Farmington Hills, Michigan, announced Sept. 4 that it had successfully enrolled 39 glaucoma patients at five US sites from late May to August 2019 for the ORION-1 Phase IIb tria...

STAAR Surgical Announces Strategic Alliance Agreement with Asian Eye Institute

STAAR Surgical, of Lake Forest, California, announced Sept. 4 that it had entered a strategic alliance with Asian Eye Institute, an eye care group with nine locations in the Philippines. Robert “Bo...

Regenxbio to Evaluate Clearside’s Suprachoroidal Delivery Platform for RGX-314 Gene Therapy in DR, Wet AMD

Regenxbio will evaluate Clearside Biomedical’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration (AMD), diabetic retinopathy (D...

Orthopedic US FDA 510(k) Clearances

During the past month, 50 orthopedic medical devices have received FDA clearance. One-third of the devices (17) are spine implants. Seven of the spine devices cleared are for fixation, including on...

CMS Coverage Proposals for 2020 Favor Outpatient Procedures

The US Centers for Medicare and Medicaid Services (CMS) published proposed 2020 rules for review in August. Arguably, the most pertinent changes for orthopedics fall in the Hospital Outpatient Pros...

Surgical Robots Widely Viewed as Competitive Advantage

Orthopedic manufacturers increasingly view the development of surgical robots as a primary growth strategy. Robots are a rapidly growing market segment on their own, but the potential for pull-thro...

Latest Orthopedic Market Deals

Over $550 million in deals took place between Aug. 2 and Sept. 4. The largest disclosed transaction amount, by far, is Stryker’s acquisition of Mobius Imaging and Cardan Robotics. Stryker will pay ...

Health Care Professionals From Over 80 Countries Expected to Attend EUROSPINE 2019

The 2019 EUROSPINE congress will be held Oct. 16-18 in Helsinki, Finland. Over 2,300 physicians and health care professionals are expected to attend the three-day meeting, along with 1,400 industry...

NASS Meeting in Windy City Expects Over 6 Thousand

The North American Spine Society will hold its 34th annual meeting from Sept. 25-28 in Chicago, Illinois. Over 3,200 attendees are expected to attend, along with a similar number of exhibitors from...

Q2-2019 Overall Market Increases Despite Drop in Neuromodulation Revenue

Overall orthopedic industry revenue increased 0.9 percent in Q2-2019 compared with Q2-2018, largely due to a 4.9 percent decline in the neuromodulation market. This drop was somewhat offset by gain...

New SpeedSpiral CMC Allograft System Is Designed to Treat Arthritis and Preserve Pinch Strength

Arthrosurface, a company focused on preserving joints, announced July 10 that its new SpeedSpiral CMC (carpometacarpal) System has launched. Lester Fehr, VP of business development, discussed the u...

FDA Warns Patients, Doctors Against Use of Recalled Compounded Drugs from AmEx Pharmacy

The US FDA is reminding patients and health care professionals not to use drug products intended to be sterile made by Pacifico National Inc., an outsourcing facility doing business as AmEx Pharmac...

iSTAR Medical Raises $44.1 Million in Series C for MINIject MIGS Candidate

Belgium-based iSTAR Medical announced Sept. 5 that it has raised $44.1 million (€40 million) in a Series C financing to advance its MINIject implant for glaucoma in the US and Europe. The MINIject ...

Lenstec Completes US Pivotal Trial of SBL-3 IOL

St. Petersburg, Florida-based Lenstec reported Aug. 30 that it has completed its US FDA pivotal trial for its SBL-3 segmented bifocal lens. The asymmetric multifocal IOL is designed to provide good...

UK’s NICE Recommends Luxturna Retinal Gene Therapy

The UK’s health care cost watchdog, the National Institute for Health and Care Excellence (NICE), has recommended Novartis’ Luxturna gene therapy for patients with retinal dystrophy caused by mutat...

Gyroscope Secures $61 Million in Series B to Advance Gene Therapy for Dry AMD

Gyroscope Therapeutics has secured $61 million (£50.4 million) in a Series B round to continue development of a potential retinal gene therapy and surgical delivery system. The UK-based company ann...

Aerie Upsizes Private Offering to $275 Million in Convertible Notes Due in 2024

Aerie Pharmaceuticals, of Durham, North Carolina, announced Sept. 4 that it plans to raise $275 million in the sale of convertible senior notes due in 2024. The offering was increased from $250 mil...

Sight Sciences Raises $56 Million to Boost OMNI Glaucoma Surgical System and TearCare for Dry Eye

Sight Sciences, of Menlo Park, California, announced Sept. 4 the closing of $31 million in a Series D Preferred Stock financing led by KCK Group, a leading investor in medical technology companies....

Topcon Launches the Maestro2 with Automated OCTA

Topcon announced Aug. 27 the launch of the Maestro2 automated OCT/fundus camera, now with OCTA. The Maestro2 is a fully automated OCT system that can capture high-resolution, nonmydriatic, true col...

Alphatec and Its CEO Cleared of NuVasive's Allegations

Alphatec Holdings announced Aug. 27 that the Delaware Chancery Court extinguished all non-competition and non-solicitation claims that NuVasive brought against Alphatec and its CEO, Pat Miles. Mile...

DiscGenics Receives US FDA Fast Track Designation

The US FDA granted Fast Track designation to DiscGenics’ injectable disc cell therapy (IDCT), the company announced Aug. 26. Fast Track status may be granted to products with sufficient preclinical...

Martha Will Succeed Ishrak as Medtronic CEO at End of Fiscal Year

Medtronic said Aug. 28 that Omar Ishrak will retire as CEO at the end of this fiscal year. Ishrak will remain chairman of the board and become the executive chairman of Medtronic. Geoff Martha, cur...

Relievant Medsystems Achieves Positive Results in Multicenter Study

Relievant Medsystems announced Aug. 27 that results from its prospective, open-label, single-arm, multicenter study were published in the European Spine Journal. Twenty-eight patients with chronic ...

Innovations Will Propel OCT Market to $559 Million in Revenue in 2019

Recent innovations in optical coherence tomography (OCT) technology—such as systems that are combined with fundus imagers—and software advancements, including OCT angiography, are growing in popula...

Alcon Launches PanOptix Trifocal IOL in US

Alcon introduced its PanOptix trifocal lens in the US on Aug. 27 after gaining FDA approval for the lens. The PanOptix is the only trifocal IOL available in the US. Alcon said it plans to begin tra...

Scientists Use CRISPR to Create Reptile Model to Study Foveal Defects in Albinism

Scientists have used CRISPR gene editing in a type of lizard to create the first suitable animal model for researchers looking to manipulate the tyrosinase gene to study foveal defects in albinism....

Scientists Test Implant to Stimulate Optic Nerve in Blind Patients

STAAR to Begin US Clinical Trial of EVO and EVO+ Visian ICLs

Laser Company Optotek Medical is Acquired by its Biggest Customer, Quantel Medical

French laser company Lumibird announced Aug. 26 that its subsidiary Quantel Medical had acquired the Slovenian firm Optotek Medical, specializing in developing optical and laser solutions for medic...

ONL Therapeutics Raises $3 Million in Convertible Note to Advance ONL1204 into First-In-Human Clinical Study

ONL Therapeutics, of Ann Arbor, Michigan, announced Aug. 22 that it had recently raised $3 million in a convertible note financing. Participating was a mix of current investors, ONL management, and...

Want to Read Locked Articles?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.